2 active not recruiting, 1 recruiting. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Mucosal Melanoma: new trials by email Literature Review of Recurrent Mucosal Melanoma trials Research Report on Recurrent Mucosal Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Anal Melanoma, Bladder Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 101 | 2022-08-11 | 2026-08-04 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
Melanoma (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Neuroendocrine Tumors (2) · Nevi and Melanomas (2) · Skin Diseases (2) · Skin Neoplasms (2) · Skin and Connective Tissue Diseases (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplastic Processes (1)
Magnetic Resonance Spectroscopy (3) · Nivolumab (2) · Specimen Handling (2) · Biopsy (1) · CTLA-4 Antigen (1) · Interferon alpha-2 (1) · Introns (1) · Ipilimumab (1) · cabozantinib (1) · pembrolizumab (1) · poly ICLC (1) · ruxolitinib (1)
National Cancer Institute (NCI) (2) · Fred Hutchinson Cancer Center (1)
United States (3) · Canada (2) · Ireland (1)
Alexander N Shoushtari (1) · Joshua Veatch (1) · Sapna Patel (1)
U10CA180821 (1), U10CA180888 (1)